Reported financial results for the fourth quarter and full year ended December 31, 2025. The FDA stated that Phase I/II data for AMT-130, an investigational gene therapy for Huntington's disease, are insufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. The company plans to request a Type B meeting with the FDA in the second quarter of 2026 to further discuss potential Phase III study design approaches for AMT-130. Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026. Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity, but paused additional dosing in midand high-dose cohorts due to dose-limiting liver enzyme elevations. Enrollment for AMT-162 for SOD1 amyotrophic lateral sclerosis (ALS) remains on voluntary pause following an Independent Data Monitoring Committee recommendation after review of preliminary safety and efficacy data, which included one serious adverse event of dose-limiting toxicity. Cash, cash equivalents, and current investment securities were approximately $622.5 million as of December 31, 2025, expected to fund operations into the second half of 2029. Net loss for the year ending December 31, 2025, was $199.0 million, an improvement from a $239.6 million net loss in 2024. Revenue for 2025 was $16.1 million, a decrease from $27.1 million in 2024. Research and development expenses decreased slightly to $140.7 million in 2025 from $143.8 million in 2024. Selling, general and administrative expenses increased to $65.5 million in 2025 from $52.7 million in 2024, partly due to preparation for AMT-130 commercialization.